Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial mu-opioid receptor agonist (buprenorphine) and mu-opioid receptor antagonist (naloxone). Buprenorphine has high affinity but low intrinsic activity at mu receptors, producing ceiling effects on respiratory depression and euphoria. Naloxone antagonizes opioid effects and is poorly absorbed sublingually, added to discourage parenteral abuse.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Treatment of opioid dependence (FDA-approved),Off-label: chronic pain (buprenorphine alone)
Mild to moderate pain,Fever
Sublingual: 2/0.5 mg to 4/1 mg once daily initially; titrate up to 8/2 mg, 12/3 mg, or 16/4 mg once daily; maximum 24/6 mg once daily. Buccal: 2.1/0.3 mg once daily initially; titrate up to 4.2/0.7 mg, 8.4/1.4 mg, or 12.6/2.1 mg once daily; maximum 12.6/2.1 mg once daily.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Buprenorphine: terminal half-life 24-60 hours (mean ~37 h) due to slow dissociation from opioid receptors; clinically relevant for once-daily or alternate-day dosing. Naloxone: terminal half-life 1-2 hours; rapid elimination limits oral systemic availability.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily via N-dealkylation by CYP3A4 to norbuprenorphine (active metabolite); also glucuronidation by UGT1A1, UGT2B7, UGT1A3. Naloxone is extensively metabolized in the liver, primarily by glucuronidation.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Buprenorphine: primarily fecal (69-70%) via biliary excretion; renal (10-30%) as unchanged drug and metabolites. Naloxone: extensively metabolized in liver, primarily conjugated; renal excretion of metabolites (70%), minimal unchanged (<1%).
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Buprenorphine: ~96% bound primarily to alpha- and beta-globulins, also to albumin. Naloxone: ~45% bound to plasma proteins (mainly albumin).
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Buprenorphine: Vd ~3-5 L/kg; high due to lipophilicity and extensive tissue distribution. Naloxone: Vd ~2 L/kg; moderate distribution.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Sublingual buprenorphine: ~30-50% (range 15-70%). Oral buprenorphine: <10% due to first-pass metabolism. Sublingual naloxone: <2% due to extensive first-pass; negligible under normal conditions, but sufficient to precipitate withdrawal if injected.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
No dose adjustment required for mild-moderate renal impairment (GFR >=30 m L/min). For severe renal impairment (GFR <30 m L/min), initiate with low doses and titrate cautiously; buprenorphine is highly protein bound but naloxone may accumulate.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh A: no adjustment. Child-Pugh B: use lower initial doses (e.g., 2/0.5 mg sublingual) and titrate slowly. Child-Pugh C: contraindicated due to risk of accumulation and prolonged effects.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Approved for ages >=16 years: dosing same as adults, but start at lowest possible dose (e.g., 2/0.5 mg sublingual) and titrate based on response. For <16 years: safety and efficacy not established.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Use with caution; start at low end of dosing range (e.g., 2/0.5 mg sublingual) and titrate slowly due to increased sensitivity, risk of respiratory depression, falls, and cognitive impairment. Monitor renal and hepatic function.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Risk of serious respiratory depression, especially during initiation or dose escalation. Concomitant use with CNS depressants (e.g., benzodiazepines, alcohol) may lead to profound sedation, respiratory depression, coma, and death. Neonatal opioid withdrawal syndrome may occur if used during pregnancy. Accidental ingestion, especially by children, can cause fatal respiratory depression.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Risk of respiratory depression, misuse/abuse, dependence, and withdrawal if abruptly discontinued. Adrenal insufficiency, hepatotoxicity (rare), QTc prolongation (buprenorphine high doses), and precipitation of withdrawal if given too soon after full agonist opioids. Use caution in patients with hepatic impairment, biliary tract disease, or head injury.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to buprenorphine or naloxone. Significant respiratory depression. Acute or severe bronchial asthma. Known or suspected gastrointestinal obstruction. Concomitant use with MAOIs or within 14 days of MAOI use (relative).
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
No specific food interactions. Grapefruit juice may increase buprenorphine levels via CYP3A4 inhibition; avoid excessive consumption. Avoid alcohol-containing foods or beverages due to additive CNS depression.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Pregnancy Category C. First trimester: Limited human data; animal studies show reduced fetal growth and increased fetal loss at high doses. Second and third trimesters: Chronic exposure may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at delivery. Not associated with major malformations.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Buprenorphine is excreted in breast milk with an estimated average infant dose of 1-2% of maternal weight-adjusted dose. Naloxone has poor oral bioavailability. M/P ratio: buprenorphine ~0.6-1.0. Generally considered compatible with breastfeeding, but monitor infant for drowsiness, respiratory depression, and feeding difficulties.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No standard dose adjustment required in pregnancy, but pharmacokinetic changes (increased clearance, volume of distribution) may necessitate splitting total daily dose into 3-4 doses to avoid withdrawal symptoms. Individualize based on clinical response and signs of withdrawal.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Buprenorphine/naloxone is a partial mu-opioid agonist with a ceiling effect on respiratory depression, reducing abuse potential but requiring careful induction in opioid-dependent patients to avoid precipitated withdrawal. Sublingual administration bypasses first-pass metabolism; naloxone has poor sublingual bioavailability but precipitates withdrawal if injected parenterally. Monitor hepatic function due to rare hepatotoxicity. Avoid use in severe hepatic impairment. The combination is preferred over buprenorphine alone to deter diversion. Dose adjustments may be needed in renal impairment. Pregnancy: not recommended unless benefit outweighs risk; can cause neonatal opioid withdrawal syndrome.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take this medication exactly as prescribed under the tongue; do not chew or swallow it.,Do not inject or snort the medication; this can cause severe withdrawal or overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines) as they increase risk of respiratory depression.,Store the medication securely and out of reach of children; properly dispose of unused medication via a take-back program.,Do not stop abruptly; withdrawal symptoms may occur. Follow your provider's tapering plan.,Inform all healthcare providers that you are taking this medication.,Seek emergency care if you experience difficulty breathing, severe drowsiness, or signs of allergic reaction.,This medication is part of a comprehensive treatment plan including counseling and behavioral therapy.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE vs ACEPHEN, answered by our medical review team.
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE is a Opioid Antagonist that works by Partial mu-opioid receptor agonist (buprenorphine) and mu-opioid receptor antagonist (naloxone). Buprenorphine has high affinity but low intrinsic activity at mu receptors, producing ceiling effects on respiratory depression and euphoria. Naloxone antagonizes opioid effects and is poorly absorbed sublingually, added to discourage parenteral abuse.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE is: Sublingual: 2/0.5 mg to 4/1 mg once daily initially; titrate up to 8/2 mg, 12/3 mg, or 16/4 mg once daily; maximum 24/6 mg once daily. Buccal: 2.1/0.3 mg once daily initially; titrate up to 4.2/0.7 mg, 8.4/1.4 mg, or 12.6/2.1 mg once daily; maximum 12.6/2.1 mg once daily.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show reduced fetal growth and increased fetal loss at high doses. Second and third trimesters: Chronic exp. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.